Cellular immune therapy for refractory cancers: Novel therapeutic strategies

Experimental Hematology

Volumn 33, Issue 12, 2005, Pages 1427-1435

  Ballen, Karen K ^a   Colvin, Gerald ^b   Dey, Bimalangshu R ^a   Porter, David ^c   Westervelt, Peter ^d   Spitzer, Thomas R ^a   Quesenberry, Peter J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d University of Massachusetts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IDARUBICIN; MELPHALAN; METHOTREXATE; SIPLIZUMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD CELL; BONE MARROW TOXICITY; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CELLULAR IMMUNITY; CHIMERA; CORD BLOOD STEM CELL TRANSPLANTATION; CORRELATION ANALYSIS; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; KIDNEY CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SOLID TUMOR; WHOLE BODY RADIATION;

ANIMALS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; SALVAGE THERAPY; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 28844481895     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2005.06.032     Document Type: Review

References (54)

1. F.M. Stewart, R.B. Crittenden, P.A. Lowry, S. Pearson-White, and P.J. Quesenberry Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice Blood 81 1993 2566 2571
2. F.M. Stewart, S. Zhong, J. Wuu, C.C. Hsieh, S.K. Nilsson, and P.J. Quesenberry Lymphohematopoietic engraftment in minimally myeloablated hosts Blood 91 1998 3681 3687
3. P.J. Quesenberry, S. Zhong, H. Wang, and F.M. Stewart Allogeneic chimerism with low dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice Blood 97 2001 557 564
4. G.A. Colvin, J.F. Lambert, and M. Abedi Murine marrow cellularity and the concept of stem cell competition: geographic and quantitative determinants in stem cell biology Leukemia 18 2004 575 583
5. J.F. Lambert, G.A. Colvin, and S. Zhong H-2 mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation Br J Hematol 119 2002 155 163
6. H. Kolb, J. Mittermuller, and C. Clemm Donor leukocyte transfusions for treatment of recurrent chronic myelogeneous leukemia in marrow transplant patients Blood 76 1990 2462 2465
7. D. Porter, R. Collins, and O. Shilberg Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions Biol Blood Marrow Transplant 5 1999 253 261
8. D.L. Porter, M.S. Roth, and C. McGarigle Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia N Engl J Med 330 1994 100 106
9. S. Slavin, A. Nagler, and E. Naparstek Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756 763
10. I.F. Khouri, R.M. Saliba, and S.A. Giralt Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality Blood 98 2001 3595 3599
11. T.R. Spitzer, S. McAfee, and B.R. Dey Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies Transplantation 75 2003 1748 1752
12. B.R. Dey, S. McAfee, and R. Sackstein Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation Biol Blood Marrow Transplant 7 2001 604 612
13. D.L. Porter, S.M. Luger, and K.M. Duffy Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation Biol Blood Marrow Transplant 7 2001 230 238
14. D.L. Porter, J.M. Connors, and V.M. Van Deerlin Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancy J Clin Oncol 17 1999 1234 1237
15. K.K. Ballen, P.S. Becker, and R.V.B. Emmons Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy Blood 100 2002 442 450
16. M. De Lima, A. Anagnostopoulos, and M. Munsell Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 2004 865 872
17. R. Childs, A. Chernoff, and N. Contentin Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation N Engl J Med 343 2000 750 758
18. C. Carballo, N. Geller, and R. Kurlander Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors Blood 103 2004 1560 1563
19. J.O. Bay, J. Fleury, and B. Choufi Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients Bone Marrow Transplant 30 2000 95 102
20. R.F. Schipper, J. D'amaro, and M. Oudshoorn The probability of finding a suitable related donor for bone marrow transplantation in extended families Blood 87 1996 800 804
21. P. Rubinstein, L. Dobrila, and R.E. Rosenfield Processing and cryopreservation of placental-umbilical cord blood for unrelated marrow reconstitution Proc Natl Acad Sci U S A 92 1995 10119 10122
22. K.K. Ballen, M. Wilson, and H. Valinski Bigger is better: maternal and neonatal predictors of hematopoietic potential of umbilical cord blood units Bone Marrow Transplantat 27 2000 7 14
23. K.K. Ballen, J. Kurtzberg, and T.A. Lane Racial diversity with high nucleated cell counts and CD34 counts achieved in a national network of cord blood banks Biol Blood Marrow Transplant 10 2004 269 275
24. J. Kurtzberg, M. Laughlin, and M.L. Graham Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients N Engl J Med 335 1996 157 166
25. M.J. Laughlin, M. Eapen, and P. Rubinstein Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia N Engl J Med 351 2004 2265 2275
26. J.N. Barker, D.J. Weisdorf, T.E. Defor, B.R. Blazar, J.S. Miller, and J.E. Wagner Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensitiy conditioning Blood 102 2003 1915 1919
27. A. Daly, S. McAfee, and B. Dey Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants Biol Blood Marrow Transplant 9 2003 373 382
28. Y. Kanda, S. Chiba, and H. Hirai Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000) Blood 102 2003 1541 1547
29. M. Sykes, F. Preffer, and S. McAfee Mixed lymphohematopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation Lancet 353 1999 1755 1759
30. G.A. Colvin, M. Abedi, and R. Rathore Mini-haploidentical transplantation for refractory acute myeloid leukemia [abstract] Blood 140 2004 2150a
31. G.A. Colvin, R. Rathore, and J.F. Lambert HLA-haploidentical stem cell infusions for refractory hematologic malignancies: a universal outpatient immunotherapeutic approach in 100 cGy treated patients K. Dicke A. Keating Autologous Blood and Marrow Transplantation 2003 Carden Jennings Publishing Co Charlottesville, VA 267 277
32. S. Giralt, P.F. Thall, and I. Khouri Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631 637
33. N. Sacks, G. Orloff, and K. Duffy High incidence of graft-versus-host disease (GVHD) in nonmyeloablative allogeneic (NMA) stem cell transplants (SCT) with unrelated donors (UD) Proc Am Soc Clin Oncol 21 2002 282b
34. P.D. Kottaridis, D.W. Milligan, and R. Chopra In vivo CAMPATH-1H prevents graft versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2000 2419 2425
35. W. Shlomchik, M. Couzens, and C. Tang Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells Science 285 5426 1999 412 415
36. A.W. Loren, S.M. Luger, and E.A. Stadtmauer Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation Bone Marrow Transplant 35 2005 921 926
37. B.R. Dey, S. McAfee, and C. Colby Impact of prophylactic donor leukocyte infusion on mixed chimerism, graft-versus-host disease, and antitumor responses in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation Biol Blood Marrow Transplant 9 2003 320 329
38. B.R. Dey, S. McAfee, and C. Colby Anti-tumor response despite loss of donor chimerism in patients treated with nonmyeloablative conditioning and allogeneic stem cell transplantation Br J Hematol 128 2005 351 359
39. T.R. Spitzer, S. McAfee, and R. Sackstein The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched donor bone marrow transplant for refractory hematologic malignancies Biol Blood Marrow Transplant 6 2000 309 320
40. A.B. Kraus, J. Shaffer, and H.C. Toh Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation Exp Hematol 31 2003 609 621
41. M.T. Rubio, Y.M. Kim, T. Sachs, M. Mapara, G. Zhao, and M. Sykes Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived interferon gamma Blood 102 2003 2300 2307
42. M. Bregni, A. Dodero, and J. Peccatori Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer Blood 99 2002 4234 4236
43. J.O. Bay, B. Choufi, and C. Pomel Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer Bone Marrow Transplant 25 2000 681 682
44. L. Liebowitz, K.P. Lee, and C.H. June Costimulatory approaches to adoptive immunotherapy Curr Opin Oncol 10 1998 533 541
45. D. Porter, N. Bunin, and G. Laport Graft-vs-tumor induction with donor leukocyte infusions expanded ex-vivo by activation with CD3/CD28 stimulation [abstract] Blood 98 2001 404a
46. D.L. Porter Donor leukocyte infusions in acute myelogeneous leukemia Leukemia 17 2003 1035 1037
47. J. Levine, T. Braun, and S. Penza Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem cell transplantation J Clin Oncol 20 2002 405 412
48. D. Porter, B. Levine, and N. Bunin Enhancing graft-vs-tumor (GVT) activity of donor leukocyte infusions by ex-vivo expansion and activation with CD3/CD28 co-stimulation [abstract] Blood 104 2004 794a
49. L. Ruggeri, M. Capanni, and E. Urbani Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097 2100
50. D. Avigan, B. Vasir, and J. Gong Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses Clin Cancer Res 10 2004 4699 4708
51. N. Raje, T. Hideshima, and F.E. Davies Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma Br J Hematol 125 2004 343 352
52. M. Abedi, D. Greer, and D. Demers Bone marrow cells participate in regeneration of skeletal muscle by transdifferentiation to muscle cells Exp Hematol 31 suppl 1 2003 134
53. S.K. Nilsson, M.S. Dooner, and H.U. Weier Cells capable of bone production engraft from whole bone marrow transplants in nonablated mice J Exp Med 189 1999 729 734
54. D.S. Krause, N.D. Theise, and M.I. Collector Multi-organ, multi-lineage engraftment by a single bone marrow cell Cell 105 2001 369 377